Market News & Trends
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
Viridian Therapeutics, Inc. recently announced the first subject was dosed in a Phase 1/2 proof-of-concept clinical trial for VRDN-001, a monoclonal antibody that blocks the…
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine
Novavax, Inc. recently announced the European Medicines Agency (EMA) has recommended granting a conditional marketing authorization for Novavax' COVID-19 vaccine (also known as NVX-CoV2373) to…
Editas Medicine Announces FDA Clearance of IND Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia
Editas Medicine, Inc. recently announced the US FDA has cleared the IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia (TDT), enabling the company…
Eton Pharmaceuticals & ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First & Only FDA-Approved Generic Version of Carbaglu (carglumic acid)
Eton Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. recently announced the commercial launch of Carglumic Acid tablets. The product will be marketed by Eton Pharmaceuticals and…
Oral Splicing Modifiers That Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics’ Innovative Splicing Platform
PTC Therapeutics, Inc. recently announced the Nature Communications publication characterizing the novel splicing mechanism induced by compounds identified from the Huntington Disease (HD) program. These…
Poseida Therapeutics Announces FDA Clearance of IND Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors
Poseida Therapeutics, Inc. recently announced the US FDA has cleared its Investigational New Drug (IND) application for P-MUC1C-ALLO1, the company’s allogeneic CAR-T product candidate targeting…
Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Vincerx Pharma, Inc. recently announced the first patient has been dosed in the company’s Phase 1 dose-escalation study of VIP152 in relapsed or refractory (R/R)…
Hyloris Enters Strategic Partnership With Vaneltix for Treatment of Acute Pain in Interstitial Cystitis
Hyloris Pharmaceuticals SA recently announced it has entered into a strategic collaboration with Vaneltix Pharma, Inc. for the development and commercialization of Alenura as first-line…
Gerresheimer Enters Agreement With Major American Biotech to Develop Innovative Pump for Rare Diseases
Gerresheimer has recently entered into an important agreement involving its Advanced Technologies division. An established US biotech company will rely on Gerresheimer's innovative strength and…
Cerevel Therapeutics & Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia
Cerevel Therapeutics and Herophilus recently announced a phased multi-year, joint research collaboration in neuropsychiatry. The collaboration integrates the deep expertise in neuroscience drug discovery at…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….